Devyser CFTR 68 provides NHS Scotland with trustworthy, rapid results
We spoke with Dr. Andrew Purvis, Clinical Scientist for West of Scotland Centre for Genomic...
Thalassemia genetic testing has long been complex and time-consuming, requiring multiple assays and extensive hands-on work. Devyser Thalassemia v2 is designed to change that. This next-generation sequencing (NGS) solution simplifies genetic profiling by integrating alpha and beta thalassemia detection—including SNV and CNV analysis, and beta modifiers—into a single, efficient assay.
Join us to learn how Devyser Thalassemia v2 can help your laboratory:
The webinar will be followed by a live Q&A session.
A recording of this webinar will be available on-demand if you are registered.
We spoke with Dr. Andrew Purvis, Clinical Scientist for West of Scotland Centre for Genomic...
Read More
Devyser has secured a CFTR NGS proposal with UNC Hospitals. The proposal with UNC Hospitals is...
Read More
On October 26th, we hosted an insightful webinar by Prof. Milan Macek (M.D., DSc.), where he...
Read More